HLX26

anti-LAG-3 monoclonal antibody · Shanghai Henlius Biotech Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for HLX26, covering 2024-10-15 to 2025-08-06. Get the full timeline:

Most recent: Clinical Trial Update: A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients [Phase 2]

See pricing